ADMA
Research Snapshot
Static fundamentals, valuation context, and investor signals for ADMA BIOLOGICS, INC. (ADMA).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
26.7%
ROIC, 5.5% FCF margin
Growth
64.6%
5Y sales (revenue) CAGR
Balance sheet
0.2x
Debt/equity, 6.7x current ratio
Superinvestors
1
Top: Terry Smith (0.1%)
Strengths to research
- Revenue compounded at 64.6% over five years.
- Return on equity is strong at 30.8%.
- Debt/equity looks manageable at 0.2x.
- 10 annual periods are available for trend analysis.
Watchouts
- Valuation multiples are limited or unavailable.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for ADMA.
Grade D
41
/ 100
Financial Charts
No financial data available for ADMA (annual).
1 superinvestors own ADMA
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Terry Smith Fundsmith | 1,649,493 | $15M | 0.12% | 0.0% |